assay_id,year,description,assay_type,Radioligand binding (BAO_0002776),Binding (BAO_0002989),Protein activity (BAO_0013016),in vivo method (BAO_0040021),Cell phenotype (BAO_0002542),Nucleic acid binding,Antimicrobial activity,predicted_cat,prediction_score,second_largest_score
456385,2007.0,"Ex vivo anticoagulant potency in rat plasma assessed as concentration required to double prothrombin time at 30 mg/kg, po after 1 hr relative to control",F,4.415840157889761e-05,1.6877433154149912e-05,5.459508543026459e-07,0.9999997615814208,4.12816007155925e-06,4.804565492122492e-07,7.503688266297104e-07,in vivo method (BAO_0040021),0.9999997615814208,4.415840157889761e-05
2157929,2021.0,Binding affinity to NanoLuc human A1 adenosine receptor expressed in HEK293-A cells in prescence of SLV320 by NanoBRET competitive binding assay,B,0.0005386737175285,0.9998216032981871,5.657545443682466e-06,2.709032196435146e-05,9.921089804265648e-05,4.513949534157291e-05,2.979177406814415e-05,Binding (BAO_0002989),0.9998216032981871,0.0005386737175285
1907545,2019.0,Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay,F,5.598146526608616e-05,2.94988312816713e-05,3.0268677164713158e-06,3.739245948963799e-05,0.9999948740005492,4.5790795411448926e-05,0.0002272898273076,Cell phenotype (BAO_0002542),0.9999948740005492,0.0002272898273076
2265211,2022.0,Antagonist activity at human P2Y6R expressed in human 1321N1 cells assessed as inhibition of UDP-induced calcium mobilization by FLIPR assay,B,4.982932750863256e-06,3.2013138024922227e-06,0.9999920129776,3.6598887618310974e-06,9.916143426380586e-06,4.184967110631988e-06,2.9812968023179565e-06,Protein activity (BAO_0013016),0.9999920129776,9.916143426380586e-06
1614150,2016.0,Displacement of [125I]-p-iodoclonidine from I1 receptor imidazoline binding site in Sprague-Dawley rat kidney cell membranes after 30 mins by liquid scintillation counting,B,0.9999988079071044,9.383160204379236e-07,6.1634996200155e-06,1.4182934137352277e-05,8.823042662697844e-06,1.37280267153983e-05,6.848240445833653e-07,Radioligand binding (BAO_0002776),0.9999988079071044,1.4182934137352277e-05
726327,2011.0,Inhibition of STAT3 dimerization in mouse NIH3T3 cells expressing v-Src assessed as disruption of STAT3-STAT3: DNA complexation in nucleus after 30 mins by electrophoretic mobility shift assay,B,2.3502359908889048e-05,1.3215814760769716e-05,0.9998652935028076,9.89052114164224e-06,1.3303838386491409e-06,0.0006284892442636,5.581115692621097e-05,Protein activity (BAO_0013016),0.9998652935028076,0.0006284892442636
35953,1998.0,Antagonist efficacy was determined as a function (%) of maximal inhibition of an agonist in Human androgen receptor.,F,0.0002714518341235,0.0032604329753667,0.9975566864013672,0.0011330875568091,3.1074698199518025e-05,9.083452459890395e-05,0.0019075368763878,Protein activity (BAO_0013016),0.9975566864013672,0.0032604329753667
542049,2003.0,Ex vivo inhibition of intracellular interferon gamma production in T-lymphocytes of IL2-stimulated kidney transplanted cynomolgus monkey model measured before transplantation by flow cytometry,F,0.0005409324658103,8.037782390601933e-05,0.028726726770401,0.0028840000741183,0.0007123909308575,0.0017885512206703,0.0021249884739518,Protein activity (BAO_0013016),0.028726726770401,0.0028840000741183
2133132,2021.0,Inhibition of tumor metastasis in cisplatin-resistant human A549 cells assessed as upregulation of p53 expression level at 5 to 15 uM measured after 24 hrs by western blot analysis,F,0.0001262787554878,4.90911552333273e-05,0.9992665648460388,6.598879735975061e-06,0.0011941224802285,2.621862768137362e-05,4.812810948351398e-05,Protein activity (BAO_0013016),0.9992665648460388,0.0011941224802285
27450,2002.0,Displacement of [3H]DPCPX from human Adenosine A1 receptor expressed in CHO cells; range 245-370,B,0.9999992847442628,1.4828189023319285e-06,5.924133006374177e-07,2.3960340058692964e-06,3.425705017434666e-06,4.071743660460925e-06,3.839794260329654e-07,Radioligand binding (BAO_0002776),0.9999992847442628,4.071743660460925e-06
56844,1988.0,Percent increase in contractile force (CF) in anesthetized open-chest dogs iv administration of 8.75 mg/kg,F,0.0001054363965522,2.8970853236387484e-06,3.458421247160004e-07,0.9999994039535522,1.043373231368605e-05,8.308009455504362e-06,4.146279479755322e-07,in vivo method (BAO_0040021),0.9999994039535522,0.0001054363965522
1466901,2015.0,Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolate 457/11 after 18 hrs by twofold serial broth dilution method,F,4.955346594215371e-05,8.952946700446773e-06,1.5819003920114485e-06,1.5699277355452068e-05,1.6964095266303048e-06,1.0558577514530043e-06,0.9999980926513672,Antimicrobial activity,0.9999980926513672,4.955346594215371e-05
1356066,1977.0,Antimalarial activity against Plasmodium berghei infected mouse assessed as suppression of parasitemia administered through diet for 6 days,F,5.375581622502068e-06,7.363220356637612e-05,5.8976211221306585e-06,4.606764923664741e-05,2.13231533052749e-06,7.000372761467588e-07,0.999996542930603,Antimicrobial activity,0.999996542930603,7.363220356637612e-05
451078,2007.0,Induction of immune response of T-cell HNC.1 hybridoma in presence of antigen-presenting spleen cells expressing Aq assessed as drug concentration required to induce IL2 secretion after 24 hrs by ELISA,F,0.000197094224859,2.676509575394448e-05,0.000450657622423,4.234296648064628e-05,0.9993640780448914,8.499788236804307e-06,4.9835194658953696e-05,Cell phenotype (BAO_0002542),0.9993640780448914,0.000450657622423
459613,2007.0,Antifungal activity against Fusarium brasilicum assessed as mycelial growth at 15 mg/disk by filter disk method relative to control,F,9.528143709758297e-05,1.7804357412387617e-05,6.325194590317551e-06,0.0002118507982231,5.93459299125243e-06,1.691459715402743e-06,0.9999868869781494,Antimicrobial activity,0.9999868869781494,0.0002118507982231
1586506,2016.0,Inhibition of Nrf2-Keap1 (unknown origin) interaction co-expressed in HEK293T cells using D-luciferin as substrate assessed as decrease in luciferase signal intensity incubated for 24 hrs by bioluminescence-based IVIS imaging analysis,B,1.993586374737788e-05,0.0003677924978546,0.9930146932601928,0.0001596518413862,2.9255574190756303e-05,0.0021801071707159,8.477376832161099e-05,Protein activity (BAO_0013016),0.9930146932601928,0.0021801071707159
80675,1996.0,Antiviral activity against TK+VZV virus infected HEL cell lines.,F,3.731427204911597e-05,1.209758465847699e-06,1.3864787433703896e-06,5.472991233546054e-06,6.268102765716321e-07,3.72763770428719e-06,0.9999969005584716,Antimicrobial activity,0.9999969005584716,3.731427204911597e-05
220265,1997.0,Inhibitory concentration against human rotavirus MO strain,F,0.0010832719272002,0.0003599337069317,0.5296268463134766,9.440200665267184e-05,0.0966019704937934,6.83411599311512e-06,0.0924421176314354,Protein activity (BAO_0013016),0.5296268463134766,0.0966019704937934
1644000,2017.0,Inhibition of FGFR1 in human SGC7901 cells assessed as reduction in FGF-induced phosphorylation of ERK1/2 preincubated with cells followed by FGF addition by Western blot method,B,6.749705062247813e-05,2.6300176614313382e-06,0.999940037727356,1.188029818877112e-05,4.890624040854164e-06,2.382596903771628e-05,3.2703606848372146e-05,Protein activity (BAO_0013016),0.999940037727356,6.749705062247813e-05
912337,2012.0,"Antiamnesic activity in scopolamine-induced amnesia Charles Foster albino Rattus norvegicus (rat) model assessed as transfer latency time at 200 mg/kg, ip measured after 30 min by elevated plus maze test",F,1.7387648767908104e-05,6.84219548929832e-06,8.639788688924455e-07,0.9999988079071044,7.303981874429155e-06,5.044835802436864e-07,5.129971327733074e-07,in vivo method (BAO_0040021),0.9999988079071044,1.7387648767908104e-05
31974,2000.0,In vitro inhibition of human neutrophil activation against Adenosine A2A receptor; No data,F,0.0020525173749774,0.0131233157590031,0.06030835211277,1.267949573957594e-05,0.0015946392668411,7.884066144470125e-05,0.1173852309584617,Antimicrobial activity,0.1173852309584617,0.06030835211277
2109934,2021.0,Inhibition of KPC-2 (unknown origin) expressed in Escherichia coli BL21 (DE3) incubated for 3 mins by spectrophotometric analysis,B,0.0144119448959827,0.0002120717108482,0.9833887815475464,2.8950030355190397e-06,3.743426987057319e-06,1.2604145013028756e-05,0.0012776739895343,Protein activity (BAO_0013016),0.9833887815475464,0.0144119448959827
200469,1983.0,Minimum inhibitory concentration against Shigella flexneri,F,0.0003906394413206,0.0028597207274287,0.0176475718617439,3.299034869996831e-05,0.0007382410112768,0.0002744243247434,0.2222814559936523,Antimicrobial activity,0.2222814559936523,0.0176475718617439
308018,2005.0,Inhibitory activity against human Glutathione reductase relative to GSSG (100 uM),B,0.0007379885646514,3.602474635044928e-06,0.6059678792953491,3.308489976916462e-05,0.4156414270401001,1.2434456039045472e-05,0.0001834351132856,Protein activity (BAO_0013016),0.6059678792953491,0.4156414270401001
636531,2010.0,Cytotoxicity against human EKVX cells assessed as cell growth at 10 uM,F,8.703327694092877e-06,4.297058694646694e-06,5.0410158110025804e-06,1.4455783912126208e-06,0.9999970197677612,1.4168828954552737e-07,3.926999852410518e-06,Cell phenotype (BAO_0002542),0.9999970197677612,8.703327694092877e-06
873819,2012.0,Stimulation of Staphylococcus aureus FtsZ assembly and bundling at 20 ug/mL by transmission electron microscopy,B,0.0067288819700479,0.000471688224934,0.0073747215792536,0.0001371069374727,0.1347648203372955,0.0008748301770538,0.0055398754775524,Cell phenotype (BAO_0002542),0.1347648203372955,0.0073747215792536
941967,2013.0,"Antimicrobial activity against acrAB, tolC-deficient Escherichia coli str. K-12 substr. MG1655 measured after overnight incubation by serial dilution method in presence of erythromycin in iron depleted medium",F,4.672119757742621e-05,1.357194923912175e-05,3.060649532926618e-06,1.716187398415059e-05,1.2432076346158285e-06,1.6074374798336066e-05,0.9999858140945436,Antimicrobial activity,0.9999858140945436,4.672119757742621e-05
1781320,2018.0,Inhibition of human DNA topoisomerase 2 alpha-mediated DNA relaxation at 20 uM incubated for 30 mins using using pBR322 DNA substrate by ethidium bromide dye-based agarose gel electrophoresis,B,1.4480606296274344e-05,7.044357971608406e-06,0.0004185310390312,6.854408240997145e-08,4.750427615363151e-05,0.9994232654571532,0.0001718015410006,Nucleic acid binding,0.9994232654571532,0.0004185310390312
2114474,2021.0,Inhibition of HDAC in human Cal27CisR cells assessed as combination index at 0.4 uM measured in presence of 20 uM cDDP by MTT-based Chou-Talalay method,B,0.0001707185438135,5.255756332189776e-05,0.9988616704940796,4.192833148408681e-05,0.0019328531343489,0.0004615106154233,3.381356145837344e-05,Protein activity (BAO_0013016),0.9988616704940796,0.0019328531343489
643747,2010.0,Cytotoxicity against human SK-MEL-2 cells by SRB assay,F,9.156424312095623e-06,4.273181275493698e-06,4.199916475045029e-06,9.76629053184297e-07,0.9999979734420776,1.1191463045179263e-07,7.71654140407918e-06,Cell phenotype (BAO_0002542),0.9999979734420776,9.156424312095623e-06
2102748,2021.0,Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate preincubated with enzyme for 30 mins followed by substrate addition and measured after 30 mins by Ellman's method,B,6.868233322165906e-05,7.408535748254508e-05,0.9999324083328248,2.634992597450037e-05,2.907617272285279e-06,0.0001340925373369,0.000102354788396,Protein activity (BAO_0013016),0.9999324083328248,0.0001340925373369
1540049,2015.0,Cell cycle arrest in human DU145 cells assessed as accumulation at G2/M phase at 2 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 16.66%),F,8.790837455308065e-05,2.1217480025370605e-05,6.917557016095088e-08,1.8083135273627704e-06,0.999981164932251,7.308140993700363e-06,1.942743892868748e-06,Cell phenotype (BAO_0002542),0.999981164932251,8.790837455308065e-05
1564166,2016.0,Antibiofilm activity against Staphylococcus aureus clinical isolate USA300 assessed as disruption of 72 hr-preformed biofilm at 6.2 uM incubated for 24 hrs by XTT assay in presence of 1.6 uM vancomycin,F,0.0002553499653004,0.0001428641116945,1.8313632608624172e-05,4.3539825128391385e-05,2.443576704536099e-05,5.758698534918949e-05,0.999889612197876,Antimicrobial activity,0.999889612197876,0.0002553499653004
2184197,2021.0,Inhibition of IGF1R (unknown origin) at 1 uM relative to origin,B,2.249752651550807e-05,1.0979591934301425e-05,0.9999911785125732,6.656402547378093e-06,9.821835647016997e-07,1.5686167898820713e-05,7.327796629397199e-05,Protein activity (BAO_0013016),0.9999911785125732,7.327796629397199e-05
134369,1990.0,Curative activity of the Compound after oral administration at a dose of 6.6 mg/kg and I.C.E. value of 0.60; 2/5,F,3.999098225904163e-06,1.0156961252505424e-05,7.099783033481799e-06,0.9999823570251464,0.0005174765828996,3.934888809453696e-05,1.8669898054213263e-05,in vivo method (BAO_0040021),0.9999823570251464,0.0005174765828996
185110,1995.0,Effect in the anti ovulatory assay (AOA) in rats expressed as no. of rats ovulating/No of rats treated at 1.0 mg; 5/5,F,0.0002543170994613,0.0006361278356052,0.953599214553833,0.0061746919527649,0.0022602451499551,0.0032321775797754,0.0008015896310098,Protein activity (BAO_0013016),0.953599214553833,0.0061746919527649
214596,2001.0,Effective concentration required to inhibit respiratory synaptial (RSV) virus-induced cytopathicity by 50% in Vero cell lines,F,0.0001123419206123,0.0139456083998084,0.0020249942317605,0.0002100859128404,0.6119349598884583,0.000212260056287,0.0004236260429024,Cell phenotype (BAO_0002542),0.6119349598884583,0.0139456083998084
1936307,2019.0,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay,F,1.722624983813148e-05,4.62920752397622e-06,2.9647442261193646e-06,1.430538077329402e-06,0.9999985694885254,2.3020814410301682e-07,4.481398718780838e-06,Cell phenotype (BAO_0002542),0.9999985694885254,1.722624983813148e-05
1473155,2015.0,Activation of recombinant human ALDH1A3 using propionaldehyde as substrate at 20 uM preincubated for 2 mins with NAD+ followed by substrate addition by UV-Vis spectrophotometric analysis,B,6.002824011375196e-05,2.427036451990716e-05,0.9999760389328004,1.4974632449593628e-06,4.159966465522302e-06,7.3024907578655984e-06,0.0005237247678451,Protein activity (BAO_0013016),0.9999760389328004,0.0005237247678451
2353550,2023.0,Antibacterial activity against Pseudomonas aeruginosa assessed as inhibition of bacterial growth at 1.25 to 40 uM by microtiter plate reader analysis,F,4.857997282670112e-06,1.393254819959111e-06,2.656637889231206e-06,8.07655760581838e-06,6.997922810114687e-07,4.281188012100756e-06,0.9999988079071044,Antimicrobial activity,0.9999988079071044,8.07655760581838e-06
2240177,2022.0,Induction of HDAC4 degradation in human HL-60 cells at 0.1 to 10 uM after 6 hrs by Western blot analysis,B,0.000219649678911,3.401129288249649e-05,0.0262063983827829,0.0003819808480329,0.9870497584342957,4.941633505950449e-06,4.031134449178353e-05,Cell phenotype (BAO_0002542),0.9870497584342957,0.0262063983827829
183558,2002.0,"TNF-alpha inhibiting activity was assessed by In vivo inhibition of serum TNF production in rat at 50 mg/kg, peroral administration; Not tested (74% at 100 mg/kg, p.o.)",F,1.5498233551625162e-05,5.055015662946971e-06,7.043190066724492e-07,0.9999990463256836,2.140101514669368e-06,1.7630110278332722e-06,1.2647292351175563e-06,in vivo method (BAO_0040021),0.9999990463256836,1.5498233551625162e-05
1798063,2018.0,Cytoprotective activity against H2O2-induced oxidative injury in rat PC12 cells assessed as cell viability at 10 uM pretreated for 24 hrs followed by 350 uM H2O2 challenge measured after 24 hrs by MTT assay (Rvb = 60%),F,0.0001772431714925,0.0003941053582821,0.0043213139288127,0.0020988420583307,0.9838692545890808,3.204415043001063e-05,0.0019402999896556,Cell phenotype (BAO_0002542),0.9838692545890808,0.0043213139288127
706251,2009.0,Antimicrobial activity in Fusobacterium varium by CLSI agar dilution method in presence of clavulanate,F,4.0409107896266505e-05,3.484775788820116e-06,9.229207535099704e-06,0.0009461065637879,5.990237696096301e-06,2.497442210369627e-06,0.9999473094940186,Antimicrobial activity,0.9999473094940186,0.0009461065637879
2128681,2021.0,Inhibition of human N-terminal GST-fusion tagged VEGFR2 cytoplasmic domain (790 to 1356 end residues) expressed in Sf21 insect cells,B,0.0002184543991461,0.007196475751698,0.99899822473526,1.586354846949689e-05,2.805053372867405e-05,6.67781350784935e-05,4.551707752398215e-05,Protein activity (BAO_0013016),0.99899822473526,0.007196475751698
1922284,2016.0,Cytotoxicity against gefitinib-resistant human HCC827 cells assessed as inhibition of cell proliferation by MTS assay,F,1.7689240848994814e-05,4.269337296136655e-05,1.304243050981313e-05,4.219781658321153e-06,0.9999780654907228,2.87383926433904e-07,2.981900433951523e-05,Cell phenotype (BAO_0002542),0.9999780654907228,4.269337296136655e-05
1983534,2020.0,Effect on cell cycle pathway in human T47D cells assessed as fold enrichment in cell cycle genes incubated for 24 hrs relative to control,F,0.0017053213668987,0.000547063536942,0.000319638143992,0.0003203150990884,0.991337776184082,0.00132878345903,0.0001125973794842,Cell phenotype (BAO_0002542),0.991337776184082,0.0017053213668987
2034408,2021.0,Displacement of [3H]-citalopram from human SERT at 10 uM by liquid scintillation counting,B,0.9999994039535522,1.594562831996882e-06,1.8216292119177524e-06,4.424823600857053e-06,9.159953151538502e-06,1.6470601622131653e-05,1.064283992491255e-06,Radioligand binding (BAO_0002776),0.9999994039535522,1.6470601622131653e-05
55834,1987.0,Left ventricular refractory period was determined by intraduodenal administration of two dosages of 20 mg/kg of (high dose) compound in anesthetized dogs. Value was reported for experiment 2,F,1.740627794788452e-06,1.8797116354107857e-05,0.0015904300380498,0.9996967315673828,5.626115307677537e-05,4.492377740916709e-07,2.374279392824974e-05,in vivo method (BAO_0040021),0.9996967315673828,0.0015904300380498
75985,1993.0,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human ileocecal carcinoma HCT-8 cell line",F,0.0001436539605492,6.332255452434765e-06,1.6861963558767457e-06,0.001609799452126,0.9991160035133362,0.0004000312183052,0.0007115425541996,Cell phenotype (BAO_0002542),0.9991160035133362,0.001609799452126
972450,2013.0,Binding affinity to human RPA70N expressed in Escherichia coli BL21 (DE3) assessed as inhibition of interaction with FITC-Ahx-DFTADDLEELDTLAS-NH2 after 1 hr by fluorescence polarization anisotropy assay,B,0.0002816828491631,0.9999213218688964,0.0001010870328173,9.422655421076342e-05,3.1231800676323473e-05,3.004356040037237e-05,0.0002195236738771,Binding (BAO_0002989),0.9999213218688964,0.0002816828491631
2224500,2022.0,Antiproliferative activity against human SW480 cells assessed as cell growth inhibition,F,3.6848417948931456e-05,2.729261723288801e-07,1.9172748579876497e-05,0.0001230289635714,0.9999819993972778,7.88505701621034e-07,2.2246542357606813e-05,Cell phenotype (BAO_0002542),0.9999819993972778,0.0001230289635714
65537,1997.0,In vitro minimum inhibitory concentration was determined for antibacterial activity against Enterobacter cloacae p99 strain.,F,1.5629186236765236e-05,4.1694866013131104e-06,2.333370321139228e-05,0.0001803090563043,1.1380016985640395e-05,1.2132200026826467e-05,0.9999880790710448,Antimicrobial activity,0.9999880790710448,0.0001803090563043
579615,2008.0,Antimicrobial activity against Klebsiella sp. assessed as resistant isolates by CLSI breakpoint assay,F,4.011974306195043e-05,3.941132945328718e-06,1.0342829455112224e-06,7.151988029363565e-06,3.522266354138992e-07,9.232043112206156e-07,0.9999996423721312,Antimicrobial activity,0.9999996423721312,4.011974306195043e-05
1615464,2016.0,Effect on HMGB2 gene expression in serum-starved HUVEC after 24 hrs by microarray analysis relative to control,F,0.0002639568410813,0.0002490151964593,3.233155075577088e-05,0.0002418135554762,0.9999445676803588,9.092725667869672e-05,0.0003513074771035,Cell phenotype (BAO_0002542),0.9999445676803588,0.0003513074771035
56125,1984.0,Effect of compound (given intravenously) on heart rate in conscious renal hypertensive dogs at 4 h,F,9.564985521137714e-05,0.0008291849517263,0.9443357586860656,4.886564056505449e-06,0.0282388478517532,0.00167629099451,7.190626638475806e-05,Protein activity (BAO_0013016),0.9443357586860656,0.0282388478517532
1746547,2017.0,Antifungal activity against Candida albicans ATCC 44859 after 24 to 48 hrs by microdilution broth method,F,2.4113647668855265e-05,4.024930240120739e-05,5.065950972493738e-06,5.4669140808982775e-05,1.2206043720652817e-05,1.3321640608410237e-06,0.9999841451644896,Antimicrobial activity,0.9999841451644896,5.4669140808982775e-05
1341750,1977.0,Growth inhibition of mouse L1210 cells at inhibitor/deoxycytidine ratio 0.2 after 40 hrs by trypan blue exclusion assay,F,0.0031116562895476,8.51639051688835e-05,0.0180001966655254,0.0031359565909951,0.1885661780834198,0.0003722536785062,0.002215378684923,Cell phenotype (BAO_0002542),0.1885661780834198,0.0180001966655254
811800,2012.0,"Antidiabetic activity in diet-induced ICR mouse T2DM model assessed as increase in plasma insulin level at 5 mg/kg, ip after 60 mins by ELISA (Rvb = 123.5 +/- 10.2 pmol/L)",F,1.4393399396794848e-05,5.340727511793375e-06,9.234482263309474e-07,0.9999990463256836,1.030123712553177e-05,3.669709940368193e-07,4.004125457868213e-07,in vivo method (BAO_0040021),0.9999990463256836,1.4393399396794848e-05
185787,1998.0,Anticonvulsant activity was measured by maximal electroshock seizure test in rat by po administration at 50 mg/kg,F,0.0001082564485841,2.5709462079248624e-06,3.521332985201298e-07,0.9999992847442628,1.0158665645576548e-05,5.743328983953688e-06,4.496723988722806e-07,in vivo method (BAO_0040021),0.9999992847442628,0.0001082564485841
813747,2012.0,Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease D158V mutant infected in HuH7 cells,F,1.961206544365268e-05,1.541378878755495e-06,1.933422936417628e-06,5.2578925533453e-06,9.601545798432198e-07,2.77515596280864e-06,0.9999957084655762,Antimicrobial activity,0.9999957084655762,1.961206544365268e-05
1859750,2019.0,Antibacterial activity against Staphylococcus aureus NCTC12204 assessed as generation of drug resistance at 2 times MIC measured after 48 hrs by agar-based microbroth dilution method,F,3.796492819674313e-06,3.1329557259596186e-06,1.6164947282959474e-06,1.2618168511835393e-05,1.1122870091639925e-06,1.951221975105e-06,0.9999992847442628,Antimicrobial activity,0.9999992847442628,1.2618168511835393e-05
915240,1997.0,Antifeedant activity against fifth instar larvae of Spodoptera littoralis fed on compound-treated lettuce leaf at 10 ug/cm'2 by leaf-disk method,F,0.0001014883382595,0.0002690917463041,0.0035235825926065,0.0001974990591406,0.0004795499844476,7.059887138893828e-06,0.9056811332702636,Antimicrobial activity,0.9056811332702636,0.0035235825926065
1334383,1979.0,Neuroleptic activity in ip dosed Sprague-Dawley rat assessed as failure in active avoidance response measured within 30 mins,F,0.0008118620608001,0.0001175630750367,0.0038418099284172,0.7800159454345703,0.055575206875801,2.1845682567800395e-05,0.0019116220064461,in vivo method (BAO_0040021),0.7800159454345703,0.055575206875801
1366797,2014.0,Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral production at 30 uM treated 4 to 8 hrs post viral infection measured after 2 hrs by crystal violet staining-based plaque reduction assay,F,2.0070618120371364e-05,1.5667440038669156e-06,2.03793024411425e-06,3.4506274459999986e-06,9.7304871360393e-07,3.661152504719212e-06,0.9999946355819702,Antimicrobial activity,0.9999946355819702,2.0070618120371364e-05
312406,2005.0,In vitro inhibition of Plasmodium falciparum K1 (0.0024 ug/mL),F,0.0001097695421776,0.0105898166075348,0.1962606608867645,0.0060803894884884,0.332448810338974,9.88430911093019e-05,0.0292870178818702,Cell phenotype (BAO_0002542),0.332448810338974,0.1962606608867645
162041,2004.0,Inhibition of protein kinase A mediated histone phosphorylation,B,1.3230378499429207e-05,4.488187551032752e-05,0.9999960660934448,2.687292180780787e-05,4.963052333550877e-07,2.814783147186972e-05,4.389661262393929e-05,Protein activity (BAO_0013016),0.9999960660934448,4.488187551032752e-05
1839283,2019.0,Antibacterial activity against Acinetobacter baumannii isolate 1018887 measured after 24 hrs by microtiter dilution method,F,4.30186855737702e-06,1.059138412529137e-06,1.3673208059117314e-06,7.077110240061302e-06,4.148506604906288e-07,2.5907918370648986e-06,0.9999996423721312,Antimicrobial activity,0.9999996423721312,7.077110240061302e-06
1972344,2020.0,Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 20 uM measured after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (0.498%),F,3.084741183556616e-05,5.138377218827372e-06,3.050432951567928e-06,1.706501279841177e-05,0.9999938011169434,1.419716539885485e-07,7.562290647911141e-06,Cell phenotype (BAO_0002542),0.9999938011169434,3.084741183556616e-05
1906241,2019.0,Bactericidal activity against methicilline-resistant Staphylococcus aureus NRS385 USA500 incubated for 18 to 20 hrs followed by replating on tryptic soy agar plate and further incubated for 18 to 24 hrs by CLSI-based broth microdilution assay,F,5.94526864006184e-05,0.0001864882215159,5.476776550494833e-06,7.98037217464298e-05,3.461256255832268e-06,1.697246807452757e-05,0.9999899864196776,Antimicrobial activity,0.9999899864196776,0.0001864882215159
214290,1996.0,Antiviral and cytostatic effects against Sindbis virus expressed in Vero cells,F,7.510583236580715e-05,2.945396590803284e-05,2.5672230549389496e-05,6.664297416136833e-06,0.0005010140594094,9.752243204275146e-05,0.8946298956871033,Antimicrobial activity,0.8946298956871033,0.0005010140594094
991732,2013.0,Cytoprotective activity in rat L6 cells assessed as increase in glucose oxidase-reduced cell survival at 25 uM incubated for 12 hrs prior to glucose oxidase challenge measured after 5 hrs by MTT assay in presence of 23.5 mM D-glucose,F,0.0002120049903169,0.0001055926550179,0.0059519205242395,0.0389923937618732,0.840381920337677,0.0002690304245334,3.612411819631234e-05,Cell phenotype (BAO_0002542),0.840381920337677,0.0389923937618732
2252393,2022.0,Agonist activity at LRH-1 (unknown origin) transfected in human HeLa cells measured after 24 hrs by Dual Glo luciferase reporter gene assay,B,2.475404244250967e-06,1.8294409755981176e-06,0.9999945163726808,2.395453338976949e-05,1.425083269168681e-06,3.2339419703930616e-05,7.403411018458428e-06,Protein activity (BAO_0013016),0.9999945163726808,3.2339419703930616e-05
956788,2013.0,Antioxidant activity of the compound assessed as DPPH radical scavenging activity after 30 mins by spectrophotometry,F,5.208245966059621e-06,7.336704584304243e-05,0.957996666431427,0.0042555830441415,6.195015885168687e-05,5.695146683137864e-06,0.0002406607673037,Protein activity (BAO_0013016),0.957996666431427,0.0042555830441415
1772218,2018.0,Antiproliferative activity against human K562 cells after 72 hrs by CellTiter-Glo assay,F,0.0001330593222519,2.581914202437474e-07,3.637709960457869e-05,0.0001399541361024,0.9999935626983644,6.67400172460475e-07,9.050337212102022e-06,Cell phenotype (BAO_0002542),0.9999935626983644,0.0001399541361024
150010,1997.0,Percent increase in life span of p388 murine leukemia cells (inoculated i.p. on day 0) as compared to that of untreated group at 0.125 mg/kg i.p. compound dose on day 1,F,6.931828102096915e-05,9.419172783964314e-06,7.115991138562094e-06,0.9999853372573853,3.965632004110375e-06,1.191574574477272e-05,7.146506050048629e-06,in vivo method (BAO_0040021),0.9999853372573853,6.931828102096915e-05
1837015,2019.0,Inhibition of recombinant human TRKC (510 to end residues) assessed as residual activity at 10 uM using GEEPLYWSFPAKK as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control,B,9.129770660365466e-06,5.042218162998324e-06,0.9999961853027344,2.890407131417305e-06,1.0718393639308489e-07,9.576959200785495e-06,4.97119763167575e-05,Protein activity (BAO_0013016),0.9999961853027344,4.97119763167575e-05
2148298,2021.0,"Antiosteoporotic activity against OVX-induced bone loss C57BL/6 mouse model assessed as increase in microarchitectures at 10 mg/kg, po for 6 weeks by microcomputed tomography method relative to sham treated control",F,4.708344567916356e-05,2.046832196356263e-05,3.7441233757817837e-07,0.9999997615814208,5.651861556543736e-06,3.243196431412798e-07,3.072884737775894e-07,in vivo method (BAO_0040021),0.9999997615814208,4.708344567916356e-05
1799885,2018.0,Antiplasmodial activity against synchronized ring stage of chloroquine-resistant Plasmodium falciparum Dd2 infected in human erythrocytes after 48 hrs by SYBR Green 1 dye based fluorescence assay,F,0.0002015363279497,2.191550720453961e-06,2.614101140352432e-05,2.2248072127695195e-05,1.130375267166528e-06,3.4537581086624414e-05,0.9999979734420776,Antimicrobial activity,0.9999979734420776,0.0002015363279497
721924,2008.0,Antibacterial activity against beta lactamase-positive Haemophilus influenzae assessed as resistant isolates by CLSI M7-A7 broth microdilution method,F,5.786122983408859e-06,1.525493189546978e-06,1.0370997642894508e-06,5.555097231990658e-06,6.561602390320331e-07,2.310742047484382e-06,0.9999992847442628,Antimicrobial activity,0.9999992847442628,5.786122983408859e-06
1994556,2020.0,Induction of apoptosis in human T24 cells assessed as upregulation of Bcl-2 expression at 2 to 8 uM by Western blot analysis,F,2.695523653528653e-05,3.258621518398286e-06,2.7434498406364582e-06,1.5178226021816954e-05,0.9999929666519164,7.461850515255719e-08,5.818992576678284e-06,Cell phenotype (BAO_0002542),0.9999929666519164,2.695523653528653e-05
1514200,2015.0,Growth inhibition of human NCI-H460 cells by NCI standard protocol based method,F,6.544010830111802e-05,0.0010265611344948,0.003080581780523,9.005571337183937e-05,0.8085430264472961,0.0274606458842754,0.0010670429328456,Cell phenotype (BAO_0002542),0.8085430264472961,0.0274606458842754
2148810,2021.0,Stabilization of human plasma TTR assessed as inhibition of formation of high molecular weight forms of TTR with acetate buffer at pH 4 by measured at 50 uM after 72 hrs by acid-induced aggregation assay,B,0.0003485525667201,0.0144349355250597,0.0657778605818748,2.139988100680057e-05,0.0023236114066094,0.0810644775629043,0.0015730386367067,Nucleic acid binding,0.0810644775629043,0.0657778605818748
1846937,2019.0,Induction of apoptosis in human MCF7 cells assessed as viable cells at 50 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 92.1%),F,2.7982188839814626e-05,4.390008598420536e-06,2.852741772585432e-06,1.3970149666420184e-05,0.9999933242797852,1.5762365990212857e-07,7.3392634476476815e-06,Cell phenotype (BAO_0002542),0.9999933242797852,2.7982188839814626e-05
551889,1980.0,Antifungal activity against Candida albicans A15049 by 2-fold tube dilution method,F,5.2546034567058086e-05,0.0001578848605277,9.679254617367404e-06,9.523648623144254e-05,1.9273038560641e-06,2.217775090684881e-06,0.9999620914459229,Antimicrobial activity,0.9999620914459229,0.0001578848605277
928117,2012.0,Herbicidal activity against ALS-inhibiting herbicide-resistant six to eight-leaf stage Bifora radians infested wheat field at 15 to 20 g/ha applied by spraying measured after 14 to 56 days post treatment,F,0.0001253666705451,0.0002549860219005,7.064755482133478e-05,0.0693836435675621,0.0028148512355983,5.469802636071108e-05,0.8012192249298096,Antimicrobial activity,0.8012192249298096,0.0693836435675621
927252,2003.0,Herbicidal activity against Rotala indica assessed as compound application rate causing complete weed control measured 30 days after compound treatment under green house conditions,F,0.0005485213478095,8.339610212715343e-05,0.0006686915876343,0.0002957213146146,0.0004774859989993,5.375251816985838e-07,0.9770530462265016,Antimicrobial activity,0.9770530462265016,0.0006686915876343
1688178,2017.0,Displacement of [3H]U-69593 from recombinant human kappa opioid receptor expressed in CHO cell membranes after 120 mins by liquid scintillation counter analysis,B,0.9999992847442628,4.611397059761657e-07,1.7453503460274078e-06,4.3991872189508285e-06,4.747294951812364e-06,4.0162590266845655e-06,9.43145437304338e-07,Radioligand binding (BAO_0002776),0.9999992847442628,4.747294951812364e-06
90702,1998.0,In vitro anti-HIV integrase activity against integration (strand transfer) of target plasmid; Not determined,B,0.0002227652585133,0.0001384892093483,0.8144584894180298,0.0004219994880259,0.0002220595051767,6.099500387790613e-05,0.0093561289831995,Protein activity (BAO_0013016),0.8144584894180298,0.0093561289831995
804313,2012.0,Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by macrobroth dilution method in the presence of bovine serum albumin,F,5.254724328551674e-06,1.883891741272237e-06,1.2941770819452358e-06,1.0318590284441598e-05,5.369405471356004e-07,2.835374971255078e-06,0.9999994039535522,Antimicrobial activity,0.9999994039535522,1.0318590284441598e-05
922533,2013.0,Antifungal activity against Aspergillus fumigatus MTCC 343 assessed as growth inhibition by agar streak dilution method,F,6.465494516305625e-05,4.275925675756298e-05,7.757269486319274e-06,0.00024697300978,6.050234333088156e-06,1.4269339771999512e-06,0.9999910593032836,Antimicrobial activity,0.9999910593032836,0.00024697300978
384612,2006.0,Displacement of [3H]prazosin from adrenergic alpha-1A receptor in rat submaxillary gland membranes,B,0.9999995231628418,1.2274285836610943e-06,1.1185001085323163e-06,6.250383194128517e-06,6.1868208831583615e-06,6.428680990211433e-06,4.978335255145794e-07,Radioligand binding (BAO_0002776),0.9999995231628418,6.428680990211433e-06
1670221,2017.0,"Antiallodynic activity in oxaliplatin-induced Albino Swiss CD-1 mouse model of peripheral neuropathy assessed as elevation in pain sensitivity threshold at 150 mg/kg, ip administered 30 mins prior to oxaliplatin challenge relative to control",F,2.4993672923301347e-05,5.679233709088294e-06,9.72745283434051e-07,0.9999986886978148,1.3768487406196073e-05,3.778411326038622e-07,5.02617865549837e-07,in vivo method (BAO_0040021),0.9999986886978148,2.4993672923301347e-05
1670698,2017.0,"Antidiabetic nephropathic activity in db/db mouse assessed as reduction in 24 hrs urine volume at 1 to 2 mg/kg, ip administered thrice per week for 12 consecutive weeks measured at 11 weeks post dose",F,1.1412893400120083e-05,7.730853212706279e-06,5.995708534101141e-07,0.9999986886978148,6.829633093730081e-06,6.061554813641123e-07,5.89542253237596e-07,in vivo method (BAO_0040021),0.9999986886978148,1.1412893400120083e-05
2322170,2022.0,Inhibition of human HDAC3 using Boc-Lys (acetyl)-AMC as substrate pretreated with compound for 1 hrs followed by substrate addition measured after 1 hrs by microplate reader analysis,B,0.0001084148098016,0.0002081071725115,0.9997203946113586,1.4912190636096057e-05,7.17631628504023e-05,0.000134075526148,3.400120840524323e-05,Protein activity (BAO_0013016),0.9997203946113586,0.0002081071725115
47396,1999.0,Second-order rate constants for the inactivation of mammalian lysosomal cathepsin B; no inhibition,B,0.0006267530843615,0.0033530232030898,0.6515275239944458,2.608953036542516e-05,0.0465900339186191,0.0026564861182123,0.0017125778831541,Protein activity (BAO_0013016),0.6515275239944458,0.0465900339186191
693795,2010.0,Antifungal activity against Candida tropicalis 156 after 48 hrs by broth microdilution method,F,2.459204733895604e-05,2.150749969587196e-05,1.1399982213333716e-05,5.935558147029951e-05,2.8460162866394967e-06,7.623874580531265e-07,0.9999849796295166,Antimicrobial activity,0.9999849796295166,5.935558147029951e-05
978569,2013.0,Antileishmanial activity against Leishmania amazonensis MHOM/BR/77/LTB0016 promastigotes after 24 hrs by cell counting,F,0.0001381207403028,1.507882188889198e-05,1.3487488104146904e-05,4.177587106823921e-05,1.845814345813324e-08,7.996283784450497e-06,0.999997615814209,Antimicrobial activity,0.999997615814209,0.0001381207403028
2275052,2020.0,Antioxidant activity assessed as DPPH radical scavenging activity measured after 30 mins by spectrophotometric analysis,F,4.819493551622145e-05,2.328241180293844e-06,0.0241105668246746,0.0179775860160589,2.347397821722552e-05,0.0002266987576149,0.0102007267996668,Protein activity (BAO_0013016),0.0241105668246746,0.0179775860160589
1586152,2016.0,Inhibition of recombinant human C-terminal His-tagged AMPK alpha1 expressed in baculovirus infected Spodoptera frugiperda cells coexpressing human C-terminal His-tagged AMPKbeta1/gamma1 at 1 uM by radiometric assay relative to control,B,3.321014082757756e-05,0.000323725544149,0.9992585778236388,3.447519020483014e-06,9.71267809291021e-07,2.4294769900734536e-05,7.000609184615314e-05,Protein activity (BAO_0013016),0.9992585778236388,0.000323725544149
1586235,2016.0,Displacement of [3H]8-OH-DPAT from human recombinant 5HT1A receptor incubated for 1.5 hrs by microbeta scintillation counting method,B,0.9999996423721312,1.4344207102112705e-06,6.235513865249231e-07,1.6917914763325825e-05,3.4209576824650867e-06,4.73413456347771e-06,1.9047425894314076e-06,Radioligand binding (BAO_0002776),0.9999996423721312,1.6917914763325825e-05
160992,1993.0,Minimum inhibitory concentration required for antibacterial activity against Providencia,F,2.260652581753675e-05,1.802986662369221e-05,6.295201274042483e-06,4.185742000117898e-05,9.784666872292291e-06,8.516015441273339e-06,0.999990701675415,Antimicrobial activity,0.999990701675415,4.185742000117898e-05
371373,2006.0,Inhibition of beta amyloid 42 secretion in mouse N2a cells,F,0.0001359094021609,2.055859795291326e-06,0.999996542930603,9.050742846739013e-06,3.346179255458992e-06,6.0804697568528354e-05,7.24714991520159e-05,Protein activity (BAO_0013016),0.999996542930603,0.0001359094021609
410484,2006.0,Inhibition of H3 histone acetylation in human U937 cells at 100 uM,F,9.21550890780054e-05,4.279192580725066e-06,0.9999682903289796,7.377486326731741e-05,3.172026936226757e-06,3.527067747199908e-05,4.085190084879287e-06,Protein activity (BAO_0013016),0.9999682903289796,9.21550890780054e-05
907907,2012.0,Herbicidal activity against Lolium rigidum accession A11 assessed as fresh weight reduction applied at 1 times pre-emergence recommended rate applied in pots where terbufos had been incorporated into the soil relative to untreated control,F,0.0007287907646968,6.596420280402526e-05,0.0002879660460166,0.00023621643777,0.0010709924390539,2.8398537779139588e-06,0.957217574119568,Antimicrobial activity,0.957217574119568,0.0010709924390539
1693013,2017.0,Inhibition of wild-type human full length DLK (M1 to P859 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control,B,1.0515052963455672e-05,0.9999971389770508,1.2415946002874987e-05,3.359624679433182e-05,4.126067949528079e-07,5.699927896785084e-06,0.0001424333458999,Binding (BAO_0002989),0.9999971389770508,0.0001424333458999
31375,2002.0,Binding affinity towards human Adenosine A2A receptor,B,0.011829468421638,0.9996898174285888,5.49856158613693e-05,3.5912220482714474e-05,2.6009070097643416e-07,4.238987457938492e-05,0.0004622183914761,Binding (BAO_0002989),0.9996898174285888,0.011829468421638
1743090,2018.0,Anti-inflammatory activity in ip dosed C57BL/6 mouse model of DSS-induced ulcerative colitis assessed reduction in TNFalpha levels in colonic tissues co-administrated once daily with DSS measured on day 7 post dose by ELISA,F,0.0004346118366811,0.0003505672211758,0.1194094717502594,0.0217391029000282,0.2420773655176162,9.997969027608632e-05,9.122193296207116e-05,Cell phenotype (BAO_0002542),0.2420773655176162,0.1194094717502594
741339,2011.0,Inhibition of caspase 1 by fluorometric assay,B,9.138332643487956e-06,0.0006049422663636,0.999542236328125,1.1960501069552263e-05,1.4535397667714278e-06,0.000296259735478,4.1120456444332376e-05,Protein activity (BAO_0013016),0.999542236328125,0.0006049422663636
1454627,2014.0,Antagonist activity against human galectin 1 at 10 mM by fluorescence polarization assay,B,8.288580829685088e-06,3.1195673955153325e-07,0.7226942777633667,5.984293693472864e-06,0.0207528807222843,3.5243832030573685e-07,0.0017580821877345,Protein activity (BAO_0013016),0.7226942777633667,0.0207528807222843
2286370,2020.0,Growth inhibition of human OCILY10 cells at 10 uM incubated for 3 days in presence of 0.17 uM acalabrutinib relative to control,F,0.0004494557215366,0.0059213074855506,0.0036594136618077,0.0027962040621787,0.9531263709068298,9.912068344419822e-05,0.0004924923414364,Cell phenotype (BAO_0002542),0.9531263709068298,0.0059213074855506
595340,2010.0,Antiproliferative activity against human SKOV3 cells expressing adenoviral MDR1 after 48 hrs by SRB assay,F,0.000546857016161,6.381910679920111e-07,2.8032163754687645e-05,0.0001210238988278,0.999996542930603,1.245544126504683e-06,7.716460459050722e-06,Cell phenotype (BAO_0002542),0.999996542930603,0.000546857016161
504464,2003.0,DNA damaging activity against DNA repair-deficient RS 322YK (rad 52Y) yeast assessed as drug level required to produce 12 mm zone of inhibition,F,0.0001488128036726,7.158976131904637e-06,3.966052099713124e-05,1.1001655366271734e-05,3.686233321786858e-05,0.9880929589271544,0.0010497056646272,Nucleic acid binding,0.9880929589271544,0.0010497056646272
917860,2007.0,Pre-emergence herbicidal activity against Brassica napus (oilseed rape) assessed as growth inhibition at 1.5 ai kg/ha under green house conditions,F,0.0001198281242977,0.0025903941132128,0.00879917293787,0.0031049055978655,9.30882088141516e-05,0.0003225690452381,0.7185242176055908,Antimicrobial activity,0.7185242176055908,0.00879917293787
1630210,2016.0,Antibacterial activity against Staphylococcus aureus ATCC 11632 after 18 to 20 hrs by two-fold microbroth dilution method,F,3.3581839034013683e-06,3.032536596947466e-06,1.0046884426628822e-06,9.926977327268103e-06,7.883597845648183e-07,1.924304797285004e-06,0.9999995231628418,Antimicrobial activity,0.9999995231628418,9.926977327268103e-06
1676914,2017.0,Growth inhibition of human OCI-LY10 cells at 0.3 uM after 3 days in presence of 0.0003 uM ibrutinib by AlamarBlue assay (Rvb = - 2 %),F,0.0022555452305823,0.0059596020728349,0.0100607620552182,0.0097660655155777,0.9844585657119752,0.000595488178078,0.0008778194896876,Cell phenotype (BAO_0002542),0.9844585657119752,0.0100607620552182
166253,1996.0,Bioconversion to albendazole sulfonic in rats at 12 hr,F,0.0002356423501623,0.2781408429145813,9.381806012243032e-05,0.0003442307643126,0.000165957128047,0.03768215700984,0.0040481695905327,Binding (BAO_0002989),0.2781408429145813,0.03768215700984
171608,1990.0,"Neuronal selectivity expressed as Concentration in right ventricle after iv administration in rat, pretreated with 6-hydroxydopamine (control = 4.10+/-0.23)",F,0.0005295183509588,0.0048593725077807,0.0115538351237773,0.0001143159242928,0.8494784235954285,0.0844878256320953,0.0004221296403557,Cell phenotype (BAO_0002542),0.8494784235954285,0.0844878256320953
505268,2002.0,Growth inhibition of human DU145 cells,F,5.12101651111152e-05,0.0001620311377337,0.0002341749059269,0.000141390322824,0.996589422225952,2.1286652554408647e-05,0.008793618530035,Cell phenotype (BAO_0002542),0.996589422225952,0.008793618530035
565683,2009.0,Inhibition of human HDAC11,B,3.271243622293696e-05,6.448692147387192e-06,0.999995231628418,2.1995090264681494e-06,2.216677557953517e-06,3.599847332225181e-06,1.4526650375046302e-05,Protein activity (BAO_0013016),0.999995231628418,3.271243622293696e-05
2235417,2022.0,Inhibition of full length mouse recombinant MoPrP (23 to 231 residues) aggregation in RML prion infected mouse ScN2a cell lysate using PrPSc as substrate by Thioflavin T based fluorometric assay,B,3.625768658821471e-05,0.0023660878650844,0.9962186217308044,3.84562554245349e-05,9.143860370386392e-05,0.0005818107747472,0.0002306865644641,Protein activity (BAO_0013016),0.9962186217308044,0.0023660878650844
697307,2009.0,Antimicrobial activity against Beta-hemolytic Streptococcus sp. 'group A' assessed as growth inhibition at 0.12 ug/ml by broth microdilution method,F,5.734404840040952e-05,8.865535164659377e-06,2.0927086552546825e-06,1.3602736544271464e-05,1.4438343214351337e-06,1.6511979993083514e-05,0.9999940395355223,Antimicrobial activity,0.9999940395355223,5.734404840040952e-05
2110807,2021.0,Antiproliferative activity against human HCT-116 cells assessed as decrease in cell population at S-phase at 1.25 to 10 uM measured after 24 hrs by EdU incorporation based fluorescence microscopic analysis,F,3.192476651747711e-05,1.97522240341641e-06,0.0001784449268598,0.0003241696394979,0.9994847774505616,3.1671931992605096e-06,1.699692802503705e-05,Cell phenotype (BAO_0002542),0.9994847774505616,0.0003241696394979
1515666,2015.0,"Induction of diuresis in mongrel dog at 3 mg/kg, po after 24 hrs relative to control",F,5.2586841775337234e-05,1.7693220797809772e-05,5.18433239449223e-07,0.9999997615814208,5.722296918975189e-06,3.792020208948088e-07,6.340422942230362e-07,in vivo method (BAO_0040021),0.9999997615814208,5.2586841775337234e-05
1711780,2018.0,Induction of apoptotic nuclear morphological changes in human MCF7 cells assessed as induction of DNA fragmentation at 12 uM incubated for 48 hrs by DAPI nuclear staining based fluorescence microscopy,F,8.651374810142443e-05,7.073621873132652e-06,0.0004876000748481,1.238401819136925e-05,0.979492962360382,0.0031800582073628,3.2317555451299995e-05,Cell phenotype (BAO_0002542),0.979492962360382,0.0031800582073628
1495893,2015.0,Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 300 uM after 9 days by ELISA,F,2.1411986381281167e-05,1.842790993578092e-06,2.521347596484702e-06,5.201133717491757e-06,1.3956538396087126e-06,3.448748884693486e-06,0.9999940395355223,Antimicrobial activity,0.9999940395355223,2.1411986381281167e-05
1708538,2017.0,Binding affinity to ACTR3 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay,B,0.0004952462622895,0.9999614953994752,8.505131518177222e-06,0.0006591722485609,0.0003711965982802,0.0003026486374437,8.7544227426406e-05,Binding (BAO_0002989),0.9999614953994752,0.0006591722485609
219327,2001.0,Compound was tested for accumulation of (50 uM) boronated polyamines in human U251 glioblastoma cells ncubated with 5 mM DFMO,F,0.0003758448874577,0.0004998308140784,0.9318484663963318,0.0051557379774749,0.0003802191058639,0.0024975852575153,0.0144805125892162,Protein activity (BAO_0013016),0.9318484663963318,0.0144805125892162
1851198,2019.0,"Inhibition of full-length recombinant human CSK at 10 uM using poly(Glu, Tyr) 4:1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method",B,0.0013756802072748,2.9331897167139687e-05,0.9998089671134948,2.850450982805341e-05,1.9115950635750775e-05,0.000365839630831,0.0001578797528054,Protein activity (BAO_0013016),0.9998089671134948,0.0013756802072748
1523921,2015.0,Antimycobacterial activity against Mycobacterium kansasii 235/80 after 21 days,F,1.1410031220293604e-05,1.959636165338452e-06,2.3098069505067546e-05,1.68874812516151e-05,2.8807451144530205e-06,5.811477876704885e-07,0.9999947547912598,Antimicrobial activity,0.9999947547912598,2.3098069505067546e-05
182198,1993.0,Tested for the inhibition of angiotensin I (AI) pressor response after 0.5 hour following an oral dose of 10 mg/kg,F,0.0001166712099802,2.287288907609764e-06,3.685246383611229e-07,0.9999994039535522,1.5355146388174035e-05,9.391053026774898e-06,3.771074545966258e-07,in vivo method (BAO_0040021),0.9999994039535522,0.0001166712099802
768145,2011.0,"Antiparasitic activity against Fasciola hepatica infected in rat assessed as reduction in worm burden at 50 mg/kg, po administered as single dose measured after 6 days post treatment",F,3.9135840779636055e-05,1.239410903508542e-05,5.881535685148265e-07,0.9999992847442628,5.8386985983815975e-06,2.691200506887981e-07,1.3629322666020016e-06,in vivo method (BAO_0040021),0.9999992847442628,3.9135840779636055e-05
989540,2013.0,Antagonist activity at human TRPA1 expressed in CHO cells assessed as inhibition of allyl isothiocyanate-induced 45Ca2+ uptake at 1 uM incubated for 10 mins prior to allyl isothiocyanate-challenge measured after 2 to 5 mins by liquid scintillation counting analysis,B,9.23810057429364e-06,3.6529743283608695e-06,0.9999791383743286,6.411224603652954e-06,1.701848304946907e-05,4.869310032518115e-06,2.4981402475532377e-06,Protein activity (BAO_0013016),0.9999791383743286,1.701848304946907e-05
841613,2012.0,Inhibition of human recombinant COX-2 at 10 uM by ELISA,B,9.07719149836339e-05,8.728231478016824e-05,0.9999628067016602,2.3137778043746948e-05,2.6515792342252095e-05,2.6912572138826363e-05,5.310039341566153e-05,Protein activity (BAO_0013016),0.9999628067016602,9.07719149836339e-05
1665365,2017.0,Inhibition of human URAT1 expressed in HEK293T cells assessed as reduction in [14C]uric acid uptake at 30 uM after 5 mins by liquid scintillation counting method relative to control,B,0.0168203562498092,4.43811368313618e-05,0.9979515671730042,0.0001483117521274,2.342793231946416e-05,0.0001380152825731,0.0001741892046993,Protein activity (BAO_0013016),0.9979515671730042,0.0168203562498092
947690,2013.0,Mixed type inhibition of baker's yeast alpha-glucosidase by Dixon plot analysis,B,0.0001181180487037,0.0006791775231249,0.4639714360237121,0.0010503467638045,0.0003527856897562,0.000307032110868,0.0005546971806325,Protein activity (BAO_0013016),0.4639714360237121,0.0010503467638045
46520,2002.0,Inhibitory concentration of compound required against Caspase-1 compared to acylated dipeptides,B,8.607368363300338e-05,0.0048764217644929,0.0203667283058166,2.364797410336905e-06,0.0001030712519423,0.0021472596563398,0.0190194565802812,Protein activity (BAO_0013016),0.0203667283058166,0.0190194565802812
821151,2012.0,Antagonist activity at VEGFR2,F,1.8021778487309348e-06,1.196918310597539e-05,0.9999785423278807,2.980811586894561e-05,4.713213854756759e-07,4.332087428338127e-06,5.675275588146178e-06,Protein activity (BAO_0013016),0.9999785423278807,2.980811586894561e-05
987925,2013.0,Induction of apoptosis in human EC109 cells assessed as damaged cells at 5 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.1%),F,2.9167935281293467e-05,4.72624469693983e-06,2.762004669421003e-06,1.433880333934212e-05,0.9999938011169434,1.7462629386955086e-07,7.514590379287256e-06,Cell phenotype (BAO_0002542),0.9999938011169434,2.9167935281293467e-05
1360279,1977.0,"Inhibition of morphine sulfate-induced analgesic activity in Swiss-Webster mouse at 2 to 32 mg/kg, sc after 2 to 4 hrs",F,2.7620795663096945e-05,1.5466106560779735e-05,8.943968055064033e-07,0.9999994039535522,3.885774731315905e-06,1.1322784985168257e-06,5.9224939832347445e-06,in vivo method (BAO_0040021),0.9999994039535522,2.7620795663096945e-05
536504,2008.0,Inhibition of TSSK1 at 3 uM,B,1.8029506463790312e-05,1.804399744287366e-06,0.9999966621398926,3.684435114337248e-06,1.0192233048655908e-06,6.102159750298597e-05,1.3618442608276382e-05,Protein activity (BAO_0013016),0.9999966621398926,6.102159750298597e-05
2204106,2022.0,Inhibition of PI3Kalpha (unknown origin),B,1.5767216609674506e-05,1.6989627056318568e-06,0.9999985694885254,5.669578513334272e-07,9.90618360674489e-08,1.484889980929438e-05,9.42457245400874e-06,Protein activity (BAO_0013016),0.9999985694885254,1.5767216609674506e-05
1765476,2018.0,Binding affinity to transthyretin in dog serum assessed as protein occupancy at 10 uM by fluorescent probe exclusion assay,B,0.0027918850537389,0.8492090106010437,0.0009370784973725,0.0216093230992555,3.458392166066915e-05,0.0476842336356639,0.0002190369414165,Binding (BAO_0002989),0.8492090106010437,0.0476842336356639
1860372,2019.0,Inhibition of c-KIT 560 to 578 deletion mutant in human GISTT1 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 0.1 uM measured after 2 hrs by Western blot analysis,B,0.0008556703105568,0.0004946329281665,0.9937853813171388,0.0003779849503189,0.000125778344227,0.004111592657864,0.0001668442273512,Protein activity (BAO_0013016),0.9937853813171388,0.004111592657864
827807,2012.0,Growth inhibition of human Caki1 cells after 48 hrs by sulforhodamine B assay,F,4.559858280117624e-05,1.886303834908176e-05,1.865831336544943e-06,3.317158916615881e-05,0.9999955892562866,4.997902215109207e-05,0.0002620671293698,Cell phenotype (BAO_0002542),0.9999955892562866,0.0002620671293698
1892142,2019.0,"Analgesic activity in Albino Swiss CD-1 mouse model of CCI-induced neuropathic pain assessed as reduction in paw lifting latency time at 5 to 20 mg/kg, ip administered 7 days after CCI measured at 35 mins post-dose by Cold plate test",F,1.1490564247651491e-05,5.963488092675107e-06,7.285160563696991e-07,0.9999988079071044,1.1542567335709464e-05,8.136364044730726e-07,9.084303087547596e-07,in vivo method (BAO_0040021),0.9999988079071044,1.1542567335709464e-05
913285,2011.0,"Antidiabetic activity in Rattus norvegicus Wistar (rat) assessed as STZ-induced plasma glucose level at 10 mg/kg, po administered for 15 days by glucose oxidase method (Rvb = 377.3 +/- 10.5 mg/dl)",F,3.559489414328709e-05,1.6354528270312585e-05,3.974370770265523e-07,0.9999997615814208,4.791218088939786e-06,4.331941170221399e-07,4.882073767475958e-07,in vivo method (BAO_0040021),0.9999997615814208,3.559489414328709e-05
27715,2002.0,Displacement of [3H]DPCPX from human Adenosine A1 receptor expressed in CHO cells; range 213-281,B,0.9999994039535522,1.4611910046369303e-06,5.682396704287385e-07,2.326760750293033e-06,3.365917109476868e-06,4.044509751111036e-06,3.603326490519976e-07,Radioligand binding (BAO_0002776),0.9999994039535522,4.044509751111036e-06
955923,2013.0,Cytotoxicity against human HepG2 cells,F,1.035848163155606e-05,4.486017132876441e-06,1.9010607275049551e-06,6.343199174807523e-07,0.9999986886978148,9.043714044310036e-08,2.700877985262196e-06,Cell phenotype (BAO_0002542),0.9999986886978148,1.035848163155606e-05
2107031,2021.0,Antimycobacterial activity against Mycobacterium tuberculosis H37Ra 7131 incubated for 21 days by broth dilution method,F,2.1369474779930897e-05,1.0432358976686372e-05,4.510782673605718e-05,1.6489746485603973e-05,2.184214281442109e-06,1.2409013834258076e-06,0.99998140335083,Antimicrobial activity,0.99998140335083,4.510782673605718e-05
100622,1997.0,Cytotoxicity against MCF-7 cells in presence of 1 uM E2 (estradiol),F,1.1751559213735163e-05,1.808994056773372e-05,8.902980334823951e-05,3.316364200145472e-06,0.9998834133148192,5.334651973498694e-07,3.3821816032286733e-05,Cell phenotype (BAO_0002542),0.9998834133148192,8.902980334823951e-05
38889,1989.0,Inhibitory activity against beta adrenergic receptor of rat frontal cortex homogenate using (1.0 nM) [3H]- dihydroalprenolol; nd is No Data.,B,0.5914008021354675,2.227263212262187e-05,0.0212573036551475,0.0001027870166581,0.0001157569640781,0.0007994925836101,0.000262663437752,Radioligand binding (BAO_0002776),0.5914008021354675,0.0212573036551475
551767,2005.0,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 after 48 hrs,F,0.0001419628533767,9.036788242156036e-07,2.998962736455724e-05,4.5020202378509566e-05,1.4695281151944073e-06,2.4272561859106645e-05,0.9999988079071044,Antimicrobial activity,0.9999988079071044,0.0001419628533767
188317,1986.0,DOM appropriate responses per min when compound administered at 12 mg/kg,F,0.0001130525852204,2.524638830436743e-06,3.5350541338630137e-07,0.9999994039535522,8.116723620332778e-06,6.61952208247385e-06,4.685521730607434e-07,in vivo method (BAO_0040021),0.9999994039535522,0.0001130525852204
1515453,2015.0,Binding affinity to dopamine D4 receptor (unknown origin) at 0.1 mM by radioligand displacement assay relative to control,B,0.9999896287918092,8.792827088655031e-07,3.913119144272059e-06,3.2537434435653267e-06,1.910751234390773e-05,1.5871402865741402e-05,9.235714060196187e-06,Radioligand binding (BAO_0002776),0.9999896287918092,1.910751234390773e-05
815412,2012.0,Ratio of IC50 for human SJSA1 cells expressing p53 to IC50 for human p53 deficient SAOS2 cells,F,0.0004928085836581,5.420364686870016e-05,0.681584894657135,8.214930858230218e-06,0.0373369567096233,0.0093624517321586,0.0015908252680674,Protein activity (BAO_0013016),0.681584894657135,0.0373369567096233
71940,1994.0,Ex vivo inhibition of U-4669 induced guinea pig platelet aggregation after 1 hr post oral administration at a dose of 10 mg/kg; Aggregation ratio = EC50 for drug/EC50 for control,F,3.21402185363695e-05,3.024374791493756e-06,2.68904796030256e-06,0.9999542236328124,0.0002576074912212,0.0001879801566246,0.0001649095502216,in vivo method (BAO_0040021),0.9999542236328124,0.0002576074912212
696331,2010.0,Inhibition of human COX1,B,2.2525522581418045e-05,4.228366378811188e-06,0.9999982118606568,1.6004175904527074e-06,7.117777158782701e-07,2.077459157590056e-06,6.06050161877647e-06,Protein activity (BAO_0013016),0.9999982118606568,2.2525522581418045e-05
790421,2011.0,Cytotoxicity against human PC3 cells,F,1.042028725350974e-05,5.769674771727296e-06,2.2882511530042397e-06,7.153892624955915e-07,0.9999984502792358,7.76479680553166e-08,3.3419951250834856e-06,Cell phenotype (BAO_0002542),0.9999984502792358,1.042028725350974e-05
554654,2007.0,"Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolate-2 with gyrA Ser81Phe, Ser114Gly, ParC Ser52Gly, Ser79Phe, Asn91Asp and parE Ile460Val mutation by broth microdilution method",F,6.998963726800866e-06,2.407989313724101e-06,1.1656401284199092e-06,1.2115214303776156e-05,6.724519039380539e-07,2.3635752768313978e-06,0.9999992847442628,Antimicrobial activity,0.9999992847442628,1.2115214303776156e-05
2557,1996.0,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,0.0021258671768009,0.9957908391952516,8.832394996716175e-06,0.0005287605454213,8.906809671316296e-05,0.0009118940215557,0.0004861330380663,Binding (BAO_0002989),0.9957908391952516,0.0021258671768009
802583,2012.0,Antischistosomal activity against juvenile Schistosoma japonicum assessed as worm survival at 50 uM after 24 hrs relative to control,F,0.0009605400264263,0.0005979933193884,1.1985402124992106e-05,3.529477180563845e-05,1.846512134306977e-07,0.0001927439589053,0.965589165687561,Antimicrobial activity,0.965589165687561,0.0009605400264263
1752141,2018.0,Antiproliferative activity against human A549 cells after 24 hrs by MTT assay,F,0.0001001618511509,2.999663877290004e-07,2.4950688384706154e-05,8.494832582073286e-05,0.9999946355819702,5.440833206193929e-07,7.278338216565315e-06,Cell phenotype (BAO_0002542),0.9999946355819702,0.0001001618511509
1284364,2014.0,Antimycobacterial activity against Mycobacterium kansasii My 235/80 after 7 days,F,1.2691810297837948e-05,2.1265823306748644e-06,2.7329255317454223e-05,2.158736970159225e-05,3.4019124086626107e-06,6.755706181138521e-07,0.9999938011169434,Antimicrobial activity,0.9999938011169434,2.7329255317454223e-05
105834,2003.0,In vitro inhibitory concentration against human Melanocortin 1 receptor (MC1R),B,0.0004870363336522,0.0077181970700621,0.081626109778881,0.0004177791124675,0.030991980805993,1.6372894151572837e-06,0.0189517904072999,Protein activity (BAO_0013016),0.081626109778881,0.030991980805993
636887,2010.0,Inhibition of STK39 at 1 uM,B,0.0005096578970551,4.542338956525782e-06,0.9999665021896362,1.8565764321465397e-06,1.6927281194512034e-06,4.283843372832053e-05,9.064061305252837e-05,Protein activity (BAO_0013016),0.9999665021896362,0.0005096578970551
858048,2012.0,Inhibition of GSK3beta-mediated Tau S202/T205 phosphorylation in mouse N2A cells at 2.6 to 24 uM after 16 hrs by immunoblot analysis,B,0.0009795617079362,2.2147984054754488e-05,0.999964714050293,1.941801565408241e-05,5.3551766541204415e-06,0.0007937654736451,0.0002997280680574,Protein activity (BAO_0013016),0.999964714050293,0.0009795617079362
1675172,2017.0,Inhibition of human partial length PIK3CA Q546K mutant (R108 to N1068 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control,B,9.612865142116789e-06,0.9999955892562866,5.840219273522962e-06,1.3206339644966649e-05,8.88298586687597e-07,4.00831504521193e-06,3.7802379665663466e-05,Binding (BAO_0002989),0.9999955892562866,3.7802379665663466e-05
638216,2010.0,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at 100 uM after 24 to 72 hrs using propidium staining by flow cytometry,F,0.0001095794141292,1.999603227886837e-05,3.3313206415641616e-08,1.0006856427935418e-06,0.999984860420227,4.8104657253134064e-06,1.1417328096285928e-06,Cell phenotype (BAO_0002542),0.999984860420227,0.0001095794141292
1552318,2015.0,Antiproliferative activity against human H4 cells after 48 hrs by MTT assay,F,0.0001192481649923,3.806821951002348e-07,3.2240939617622644e-05,6.045034024282359e-05,0.999996304512024,8.869238854458672e-07,6.998089702392463e-06,Cell phenotype (BAO_0002542),0.999996304512024,0.0001192481649923
63277,2003.0,Antibacterial activity against Enterococcus faecalis W-73,F,4.266209998604609e-06,1.5351573665611795e-06,1.1772833659051685e-06,7.266700777108781e-06,3.5082231875094294e-07,1.662762088017189e-06,0.9999996423721312,Antimicrobial activity,0.9999996423721312,7.266700777108781e-06
191026,1994.0,Serum glucose level in STZ-male wistar rats treated orally for 1 week,F,0.0004702298901975,0.156655341386795,0.002585329581052,0.0134822269901633,0.0706814527511596,0.0003503143088892,0.0007217474048957,Binding (BAO_0002989),0.156655341386795,0.0706814527511596
2080017,2021.0,Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by XTT assay,F,0.0001050250939442,8.279647545350599e-07,3.1808904168428853e-06,4.9692542233970016e-05,0.999991774559021,5.615156624116935e-06,0.0001448554685339,Cell phenotype (BAO_0002542),0.999991774559021,0.0001448554685339
62479,2004.0,Binding affinity to dopamine transporter (DAT) in rat forebrain tissue,B,0.0002146532788174,0.990957498550415,3.311813634354621e-05,0.0003748887102119,0.000405740662245,0.0233143158257007,0.0011664134217426,Binding (BAO_0002989),0.990957498550415,0.0233143158257007
2117510,2021.0,Cell cycle arrest in human U-87 MG cells assessed as accumulation at G2/M phase at 8 uM incubated for 48 hrs by PI staining based flow cytometry assay (Rvb = 8%),F,9.771242184797302e-05,2.182700154662598e-05,8.567577935991721e-08,2.0708284864667803e-06,0.999980092048645,8.298293323605321e-06,2.118879592671874e-06,Cell phenotype (BAO_0002542),0.999980092048645,9.771242184797302e-05
1903169,2020.0,Inhibition of GRK5 (unknown origin) at 1 uM relative to control,B,4.135874041821808e-05,3.711572389875073e-06,0.9999960660934448,4.887920567853144e-06,5.068117161499686e-07,2.1357984223868694e-05,1.582639197295066e-05,Protein activity (BAO_0013016),0.9999960660934448,4.135874041821808e-05
2083070,2021.0,Growth inhibition of human RXF 393 cells at 10 uM incubated for 48 hrs by sulforhodamine B assay relative to control,F,4.034930680063553e-05,4.498561247601174e-05,1.960498047992587e-05,4.395685027702712e-05,0.9999946355819702,6.258414941839874e-05,0.0002634519769344,Cell phenotype (BAO_0002542),0.9999946355819702,0.0002634519769344
2315302,2023.0,Binding affinity to HDAC3 (unknown origin) assessed as binding constant(k2),B,2.6496580176171847e-05,0.999958872795105,7.58216856411309e-07,5.863988462806447e-06,3.262172413087683e-06,0.0011966702295467,9.586517080606429e-06,Binding (BAO_0002989),0.999958872795105,0.0011966702295467
1924496,2016.0,Antitubercular activity against Mycobacterium tuberculosis H37Rv by radiometric assay,F,0.0012939046137034,0.0003274444607086,0.0001124096525018,5.433121259557083e-05,0.0004917478072457,0.0001360395690426,0.9651707410812378,Antimicrobial activity,0.9651707410812378,0.0012939046137034
2061571,2016.0,Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay,F,7.508979615522549e-05,3.347803794895299e-05,1.9368555967957946e-06,5.0404531066305935e-05,0.9999954700469972,7.49282116885297e-05,0.0002109061606461,Cell phenotype (BAO_0002542),0.9999954700469972,0.0002109061606461
55775,2004.0,Non-toxic dose in dogs after 4 weeks of oral administration; Not tested,F,7.897897739894688e-05,0.0001969680015463,0.5145407915115356,0.0448374450206756,0.0029197065159678,0.0014063254930078,0.0022074747830629,Protein activity (BAO_0013016),0.5145407915115356,0.0448374450206756
2284101,2018.0,Binding affinity to human recombinant ALK L1196M mutant (1093 to 1411 residues) assessed as inhibition constant using 5'FAM-KKSRGDYMTMQIG-CONH2 peptide as substrate in presence of ATP by micro-fluidic mobility shift assay,B,0.0002857420477084,0.999358594417572,4.9889211368281394e-05,6.916673737578094e-05,4.999418160878122e-05,0.0005331386346369,0.0002066845918307,Binding (BAO_0002989),0.999358594417572,0.0005331386346369
533526,2007.0,Inhibition of human trypsin at 100 uM,B,4.684142913902178e-05,3.877649305650266e-06,0.9999969005584716,4.848088337894296e-06,1.1398809647289454e-06,5.753865480073728e-06,8.350688403879758e-06,Protein activity (BAO_0013016),0.9999969005584716,4.684142913902178e-05
748380,2011.0,Antimicrobial activity against Candida tropicalis isolate 33 after 48 hrs by microdilution broth method,F,2.8335040042293255e-05,5.409167442849139e-06,6.192023533913016e-07,4.782662927027559e-06,9.028224212670466e-07,5.612976679003623e-07,0.9999995231628418,Antimicrobial activity,0.9999995231628418,2.8335040042293255e-05
631491,2010.0,Displacement of [3H]estradiol from human ERalpha expressed in african green monkey COS1 cells assessed as relative binding affinity after 2 hrs by liquid scintillation counting relative to estradiol,B,0.9999992847442628,1.4363945410877932e-06,2.272787924084696e-06,1.7638941471886938e-06,5.251437414699467e-06,1.0465822015248705e-05,4.0216941670223605e-06,Radioligand binding (BAO_0002776),0.9999992847442628,1.0465822015248705e-05
659332,2010.0,Inhibition of c-Kit by HTRF assay,B,0.0001320826559094,2.2076312689023325e-06,0.9999359846115112,1.0271572136844044e-05,1.6383470210712403e-05,0.0008033667691051,0.0001715093967504,Protein activity (BAO_0013016),0.9999359846115112,0.0008033667691051
1725534,2017.0,"In vivo inhibition of NMD in BALB/cA Jc1 nude mouse xenografted with human HCT116 cells assessed as upregulation of SC35 1.6 kb mRNA expression level in tumor at 100 mg/kg, po administered as single dose measured after 8 hrs by qPCR analysis relative to control",F,5.9625570429489017e-05,1.432232056686189e-05,5.121900699123216e-07,0.9999996423721312,7.256374829012202e-06,1.628122987540337e-07,4.085062528247363e-07,in vivo method (BAO_0040021),0.9999996423721312,5.9625570429489017e-05
110028,1986.0,Effective dose in mice by horizontal screen assay (administered orally); No effect at highest dose of 400 mg/kg,F,0.0001320762239629,1.412126835020899e-06,4.8456661261298e-07,0.9999992847442628,8.484797035634983e-06,3.689240884341416e-06,3.794726239902957e-07,in vivo method (BAO_0040021),0.9999992847442628,0.0001320762239629
31511,2002.0,Displacement of [3H]SCH-58261 from human Adenosine A2A receptor expressed in HEK293 cells; range 103-142,B,0.9999996423721312,2.009169065786409e-06,5.135497644914722e-07,1.749481634760741e-05,1.6658916138112545e-05,9.107125151786022e-06,2.4298651624121703e-06,Radioligand binding (BAO_0002776),0.9999996423721312,1.749481634760741e-05
572241,2009.0,Inhibition of human ELOVL1 expressed in Pichia pastoris SND1168,B,3.7638423236785457e-05,7.858655408199411e-06,0.9999940395355223,2.7723917810362764e-06,3.4066620173689444e-06,5.767049970017979e-06,1.4081530935072806e-05,Protein activity (BAO_0013016),0.9999940395355223,3.7638423236785457e-05
1571633,2016.0,Induction of cell cycle arrest in human HCT116 cells assessed as accumulation at G1 phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 28%),F,5.577955744229257e-05,5.8425834140507504e-05,5.009979213355109e-05,0.0001376524014631,0.9999005794525146,0.0002129748318111,2.193151885876432e-05,Cell phenotype (BAO_0002542),0.9999005794525146,0.0002129748318111
371968,2006.0,Binding affinity to ERbeta by scintillation proximity assay,B,6.854676030343398e-05,0.999523401260376,2.8333206500974484e-06,3.103161361650564e-05,2.5306242150691105e-06,0.0004838472232222,0.0004539966466836,Binding (BAO_0002989),0.999523401260376,0.0004838472232222
927142,2013.0,Herbicidal activity against Capsella bursa-pastoris in wheat cultivar Dongmai 12 field assessed as decrease in biomass applied during late tillering stage of winter wheatat 525 g ai/h measured after 45 days under field trials,F,0.000986227649264,0.0002686244260985,0.0005342666991055,0.0003313733905088,0.0005447841831482,9.098610007640672e-07,0.9472734928131104,Antimicrobial activity,0.9472734928131104,0.000986227649264
112188,1995.0,"The compound was evaluated for the median survival time (MST) in mice infected with cisplatin sensitive L1210 Leukemia (dose 80 mg/kg, ip), day 9",F,1.3262604625197127e-05,6.756371476512868e-06,8.411676617470221e-07,0.9999994039535522,7.612036370119313e-06,7.671683306398336e-07,7.193957571871579e-07,in vivo method (BAO_0040021),0.9999994039535522,1.3262604625197127e-05
320750,2005.0,Inhibition constant against histamine H3 receptor,B,0.000111959176138,0.0001634291693335,0.7612377405166626,2.5357192043884424e-06,7.30802639736794e-05,0.0197140239179134,0.000285300775431,Protein activity (BAO_0013016),0.7612377405166626,0.0197140239179134
433677,2007.0,Antimicrobial activity against Pseudomonas aeruginosa 19C5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient,F,4.0176713810069486e-05,4.2122833292523865e-06,1.4548030549121904e-06,5.462025910674129e-06,8.282545991278312e-07,1.0211613243882312e-06,0.9999994039535522,Antimicrobial activity,0.9999994039535522,4.0176713810069486e-05
547235,2004.0,Growth inhibition of human MCF7 cells after 48 hrs by SRB assay,F,0.0037237615324556,7.571867172373459e-05,9.687990313977934e-06,4.082050872966647e-05,0.9999958276748656,0.0002010484313359,9.046102059073746e-05,Cell phenotype (BAO_0002542),0.9999958276748656,0.0037237615324556
696401,2010.0,Antimicrobial activity against Bacillus subtilis RCMB 101001 by twofold serial dilution method,F,3.182342697982676e-05,6.726950687152566e-06,1.1439997251727618e-06,6.0607617342611775e-06,7.553104524049559e-07,6.755758477083873e-07,0.9999995231628418,Antimicrobial activity,0.9999995231628418,3.182342697982676e-05
1786379,2017.0,Inhibition of ergosterol biosynthesis in fluconazole susceptible Candida albicans ATCC 90028 at 8 ug/ml relative to control,F,1.58871498570079e-05,1.391272871842375e-05,0.9999879598617554,6.64461231281166e-06,1.2306024927966064e-06,2.6049852749565616e-05,0.0001332448009634,Protein activity (BAO_0013016),0.9999879598617554,0.0001332448009634
1336952,2014.0,Inhibition of HSP90 in HEK cells expressing full-length mHtt Q73 gene assessed as reduction of mHtt level after 24 hrs by Western blot analysis,B,1.2133020391047468e-05,5.707303898816463e-06,0.9996159076690674,3.564527105481829e-06,1.335017805104144e-05,2.8555879907798957e-05,0.0001414526050211,Protein activity (BAO_0013016),0.9996159076690674,0.0001414526050211
